Search NLS News

Immunotherapy company Valo Therapeutics could play an important part in modern cancer care, using a highly adaptable platform effective for a wide range of cancers. Valo Therapeutics (ValoTx), founded in 2016, is a spin-out from Helsinki University and the research of Professor Vincenzo Cerullo. Professor Cerullo’s research group developed the unique technology platform, named PeptiCRAd […]

Ultimovacs has announced that the first patient has been randomized in the LUNGVAC study. The study in non-small cell lung cancer (NSCLC) is the fifth Phase II clinical trial in which the universal cancer vaccine, UV1, is being investigated in combination with checkpoint inhibitors. The LUNGVAC study is designed to assess the impact of UV1 […]

Imjudo in combination with Imfinzi has been approved in the US for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer. The novel dose and schedule of the combination, which includes a single dose of the anti-CTLA-4 antibody Imjudo 300mg added to the anti-PD-L1 antibody Imfinzi 1500mg […]

An investigational stem cell-based therapy for the treatment of Parkinson’s Disease, STEM-PD, has been given regulatory approval for a Phase I/IIa clinical trial. Ethical approval of the trial has already been obtained from the Swedish Ethics Review Authority, and the team, led from Lund University is thereby ready to proceed with the trial, they state. […]

This up-and-coming star on the global biotech scene aims to crack the hard code of finding better treatments for neurodegenerative diseases. The name of the company, Muna, means “to remember” in Old Norse and reflects the focus of discovering and developing medicines for neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Multiple Sclerosis and Frontotemporal Dementia. These are […]

The company has entered a material transfer agreement with the Josep Carreras Leukaemia Research Institute (JCLRI) in Spain for use of the company’s iTANK platform in arming CAR T-cells for the treatment of Ewing Sarcoma. The agreement is the first to be executed as part of Elicera’s strategy of finding collaborators and licensing partners for […]

The company has carried out a directed share issue of approximately 170 million SEK at a subscription price of SEK 72 per share. The subscription price was determined through an accelerated book-building procedure. A number of Swedish and institutional investors, including Systematic Group AB (Ashkan Pouya), Swedbank Robur Fonder, Cicero Fonder, TIN Fonder and Lancelot […]

Mendus has announced an agreement to enable the technology transfer for manufacturing of the company’s lead development program DCP-001 with Minaris Regenerative Medicine. DCP-001 is currently being evaluated in the ADVANCE II Phase 2 clinical trial to prevent cases of tumor recurrence in Acute Myeloid Leukemia (AML) and in the ALISON Phase 1 clinical trial […]

The grand opening of Health Proof Helsinki was held on 5 October 2022 at the Myllypuro campus of Metropolia University of Applied Sciences in Helsinki. Health Proof Helsinki is a a new health sector test environment ecosystem for research, development and innovation (RDI) providing companies with a service chain from early product development towards clinical […]

Zelluna Immunotherapy has announced an investment from Takeda Ventures, the strategic investing arm of Takeda. TVI investment joins Zelluna’s latest financing round, the company states. “We are delighted to have TVI as a strategic investor in Zelluna. The company has developed very well from its inception and made significant progress with our TCR-NK technology. This […]